This reiterates how I'm thinking. The timing isn't a coincidence, we're weeks away from getting CHM 2101 into the clinic. PH would obviously know how the final cohort in CHM 1101 is looking also, dosed around 14 months ago. My first thoughts were of bitter disappointment but perhaps Jen has played her role. She has been paramount in acquiring the assets and setting up the vision of the company. If CHM 2101 can replicate in human trials what it did pre-clinic, I believe we have T/O written all over us and It'll happen in the next couple of years. If we don't plan navigating the FDA process what do we need, we need someone to sell the story and that's not one of Jen's best assets.
Thank you Jen for all your hard work and expertise.
I also bought some more today.
CHM Price at posting:
2.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)